Effects of Helicobacter pylori eradication therapy on ulcer healing after gastric endoscopic submucosal dissection: a prospective randomized controlled trial.

Effects of Helicobacter pylori eradication therapy on ulcer healing after gastric endoscopic submucosal dissection: a prospective randomized controlled trial. - Effects of eradication on gastric ESD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003448

Enrollment

150

Registered

2010-04-06

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer and gastric adenoma

Interventions

Helicobacter pylori eradication before gastric ESD PPI-based triple therapy consisting of lansoprazole (60 mg), amoxicillin (1500 mg) and clarithromycin (400 mg) Helicobacter pylori eradication afte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Helicobacter pylori positive-patients with gastric cancer or gastric adenoma 1. Not less than 20 years old (no upper limit) 2.Written informed consent

Exclusion criteria

Exclusion criteria: 1)using PPIs and H2RAs 2)using anti-coagulants 3)allergy to drugs 4)severe liver dysfunction 5)severe renal dysfunction 6)Pregnant or lactating women or women

Design outcomes

Primary

Measure	Time frame
state of ulcer healing on 28 days	—

Secondary

Measure	Time frame
bleeding after ESD	—

Countries

Japan

Contacts

Public ContactShouko Ono

Hokkaido University Hospital Division of Endoscopy

onosho@med.hokudai.ac.jp011-716-1161(5723)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026